Meta-Analysis on FOLFOX plus Bevacizumab for Colorectal Cancer Treatment

Eleven randomized controlled trials were included in this systematic review and meta-analysis evaluating the safety and effectiveness of bevacizumab combined with the FOLFOX regimen for colorectal cancer. The analysis was conducted by Weiyin Ma and published on figshare, with a last update in May 2026. It pools data from PubMed, EMBASE, Web of Science, CNKI, and WanFang Database up to April 30, 2023.

Use Cases

• Compare treatment efficacy based on pooled analysis of overall response rate (ORR) and disease control rate (DCR).
• Assess safety profiles based on reported adverse events like gastrointestinal reactions, leukopenia, and hypertension.
• Inform clinical trial design based on the evidence synthesis of 11 randomized controlled trials.
• Evaluate methodological robustness based on sensitivity analyses mentioned in the results.

Strengths

• Follows PRISMA 2020 guidelines for systematic review and meta-analysis.
• Includes data from 11 randomized controlled trials.
• Searched multiple databases including PubMed, EMBASE, Web of Science, CNKI, and WanFang without language restrictions for English or Chinese studies.

Limitations

• The dataset is a 74.4 KB DOCX document, which is a small text summary rather than a raw data repository.
• Row count and column-level data are unknown; the file contains aggregated analysis results.
• The description notes substantial heterogeneity was noted for some outcomes and evidence for long-term survival benefit remains insufficient.

Provenance

Source

figshare, author Weiyin Ma.

Collection Method

Systematic review and meta-analysis of randomized controlled trials from multiple databases.

Time Range

Literature search from database inception to April 30, 2023.

Freshness

Last updated 2026-05-21 04:37:47; includes literature up to April 30, 2023.